ES2150889T1 - Una combinacion de glibenclamida-clorhidrato para el tratamiento de la diabetes mellitus de tipo ii. - Google Patents

Una combinacion de glibenclamida-clorhidrato para el tratamiento de la diabetes mellitus de tipo ii.

Info

Publication number
ES2150889T1
ES2150889T1 ES96938124T ES96938124T ES2150889T1 ES 2150889 T1 ES2150889 T1 ES 2150889T1 ES 96938124 T ES96938124 T ES 96938124T ES 96938124 T ES96938124 T ES 96938124T ES 2150889 T1 ES2150889 T1 ES 2150889T1
Authority
ES
Spain
Prior art keywords
glibenclamide
treatment
combination
type
diabetes mellitus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES96938124T
Other languages
English (en)
Other versions
ES2150889T3 (es
Inventor
Giulio Barelli
Regis Massimo De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abiogen Pharma SRL
Original Assignee
Abiogen Pharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11372517&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2150889(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abiogen Pharma SRL filed Critical Abiogen Pharma SRL
Publication of ES2150889T1 publication Critical patent/ES2150889T1/es
Application granted granted Critical
Publication of ES2150889T3 publication Critical patent/ES2150889T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE DESCRIBE UNA COMBINACION DE GLIBENCLAMIDA Y METFORMINA DE FORMA QUE, CUANDO SE ADMINISTRA EN FORMA DE COMPOSICION FARMACEUTICA EN EL TRATAMIENTO DE LA DIABETES MELLITUS DE TIPO II, LA PROPORCION ENTRE LOS DOS PRINCIPIOS ACTIVOS PERMITE OBTENER UN EFECTO TERAPEUTICO OPTIMO EN CUALQUIER MOMENTO DEL DESARROLLO DE LA ENFERMEDAD, EVITANDO EL USO DE LA TERAPIA DE INSULINA EN LOS CASOS MAS GRAVES.
ES96938124T 1995-11-14 1996-11-07 Combinacion de glibenclamida-metformina para el tratamiento de la diabetes mellitus tipo ii. Expired - Lifetime ES2150889T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI952337 1995-11-14
IT95MI002337A IT1276130B1 (it) 1995-11-14 1995-11-14 Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo

Publications (2)

Publication Number Publication Date
ES2150889T1 true ES2150889T1 (es) 2000-12-16
ES2150889T3 ES2150889T3 (es) 2004-01-01

Family

ID=11372517

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96938124T Expired - Lifetime ES2150889T3 (es) 1995-11-14 1996-11-07 Combinacion de glibenclamida-metformina para el tratamiento de la diabetes mellitus tipo ii.

Country Status (12)

Country Link
US (2) US5922769A (es)
EP (1) EP0869796B1 (es)
AT (1) ATE238802T1 (es)
AU (1) AU7566896A (es)
BR (1) BR9611448A (es)
DE (2) DE69627883T2 (es)
DK (1) DK0869796T3 (es)
ES (1) ES2150889T3 (es)
HK (1) HK1011525A1 (es)
IT (1) IT1276130B1 (es)
PT (1) PT869796E (es)
WO (1) WO1997017975A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291495B1 (en) 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
WO1999029314A1 (en) * 1997-12-08 1999-06-17 Bristol-Myers Squibb Company Novel salts of metformin and method
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
HRP990080B1 (en) * 1999-03-12 2003-04-30 Vladimir Leko Plant mixture and a medical preparation for the treatment of diabetes mellitus, type ii, obtained therefrom
PT974356E (pt) 1998-07-15 2004-02-27 Merck Sante Sas Comprimidos compreendendo uma combinacao de metformina e de glibenclamida
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
AU753933B2 (en) * 1998-09-18 2002-10-31 The, Yong Telephonic transaction system
US6958324B2 (en) * 1998-12-02 2005-10-25 Inotek Pharmaceuticals Corporation Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
US7056539B2 (en) 1999-03-12 2006-06-06 Vladimir Leko Process and product extracted from herbal composition useful in controlling diabetes mellitus type II
JP2003520759A (ja) * 1999-08-31 2003-07-08 アンドルックス ファーマスーティカルズ インコーポレーテッド 単位核を有する徐放性錠剤
CA2389928C (en) 1999-11-03 2010-03-23 Bristol-Myers Squibb Company Method for treating diabetes
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
WO2001052860A2 (en) * 2000-01-24 2001-07-26 Inotek Corporation Method and composition for modulating an immune response
KR100713234B1 (ko) * 2000-10-02 2007-05-02 유에스브이 리미티드 메트포민을 함유하는 지속방출형 약학 조성물 및 이의제조방법
US20060034922A1 (en) * 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
FR2816840B1 (fr) * 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
FR2816841B1 (fr) * 2000-11-22 2004-02-06 Lipha Nouvelles compositions pharmaceutiques a action antidiabetique et leur procede de preparation
WO2002055009A1 (en) 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Spaced drug delivery system
EP1377276B1 (en) * 2001-04-10 2011-10-05 Sun Pharma Advanced Research Company Limited Timed pulse release composition
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
BR0212150A (pt) * 2001-08-31 2004-07-13 Australian Biomedical Company Preparação e uso diabético de giberelinas
JP2005508331A (ja) * 2001-09-28 2005-03-31 サン・ファーマシューティカル・インダストリーズ・リミテッド 糖尿病の処置のための投与製剤
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
ITFI20010230A1 (it) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
WO2003061643A1 (es) 2002-01-25 2003-07-31 Laboratorios Silanes, S.A. De C.V. Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
WO2003068209A1 (en) * 2002-02-14 2003-08-21 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
AU2003228305A1 (en) * 2002-03-25 2003-10-13 Jian Luo Pharmaceutical composition with combined active agents and methods for using the same
ES2314227T7 (es) * 2002-04-09 2012-11-19 Flamel Technologies Formulacion farmaceutica oral en forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxilicina.
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
AU2003261298A1 (en) 2002-08-02 2004-02-23 Penwest Pharmaceuticals Company Sustained release formulations of metformin
FR2853831A1 (fr) * 2003-03-05 2004-10-22 Usv Ltd Forme posologique solide a usage oral de metformine et de glyburide et son procede de preparation
US20060210633A1 (en) * 2003-04-03 2006-09-21 Sun Pharmaceutical Industries Limited Programmed drug delivery system
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
CN101056656A (zh) * 2004-09-15 2007-10-17 哈佛大学校长及研究员协会 在治疗肥胖症和糖尿病中降低er应力
US20060073213A1 (en) * 2004-09-15 2006-04-06 Hotamisligil Gokhan S Reducing ER stress in the treatment of obesity and diabetes
JOP20180109A1 (ar) * 2005-09-29 2019-01-30 Novartis Ag تركيبة جديدة
FR2896157B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
WO2008062273A2 (en) * 2006-11-20 2008-05-29 Cadila Pharmaceuticals Limited Solid oral dosage form having antidiabetic drug combination
CN105030793A (zh) * 2015-08-25 2015-11-11 瑞阳制药有限公司 二甲双胍格列本脲胶囊及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2325581A1 (de) 1973-05-19 1974-12-05 Hoechst Ag Partiell hydrierte 1h-indeno eckige klammer auf 1,2-b eckige klammer zu -pyridin-derivate und verfahren zu ihrer herstellung
JPS5936885B2 (ja) 1976-06-24 1984-09-06 第一製薬株式会社 糖尿病治療剤
DE2720926C2 (de) 1977-05-10 1983-02-17 Hoechst Ag, 6000 Frankfurt Benzolsulfonylharnstoffe und Verfahren zu ihrer Herstellung
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US5260275A (en) 1990-08-14 1993-11-09 Amylin Pharmaceuticals, Inc. Hypoglycemics
JP3338119B2 (ja) 1993-04-14 2002-10-28 呉羽化学工業株式会社 抗糖尿病剤

Also Published As

Publication number Publication date
DK0869796T3 (da) 2003-08-18
USRE37330E1 (en) 2001-08-14
HK1011525A1 (en) 1999-07-16
ITMI952337A1 (it) 1997-05-14
PT869796E (pt) 2003-09-30
WO1997017975A1 (en) 1997-05-22
DE69627883T2 (de) 2004-05-19
DE69627883D1 (de) 2003-06-05
DE869796T1 (de) 2001-04-19
EP0869796B1 (en) 2003-05-02
US5922769A (en) 1999-07-13
BR9611448A (pt) 1999-03-23
IT1276130B1 (it) 1997-10-27
ITMI952337A0 (es) 1995-11-14
EP0869796A1 (en) 1998-10-14
ATE238802T1 (de) 2003-05-15
AU7566896A (en) 1997-06-05
ES2150889T3 (es) 2004-01-01

Similar Documents

Publication Publication Date Title
ES2150889T1 (es) Una combinacion de glibenclamida-clorhidrato para el tratamiento de la diabetes mellitus de tipo ii.
ES2105926B1 (es) El uso de taxol para la fabricacion de una preparacion de infusion para el tratamiento del cancer.
AR012995A1 (es) Uso de un sensibilizador a insulina y de un agente antihiperglucemico para la preparacion de medicamentos y composiciones farmaceuticas que contienedichos compuestos.
ES2542842T3 (es) Composición que comprende taurolidina y/o taurultam para el tratamiento del cáncer
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
DK372786D0 (da) Farmaceutiske praeparater af phenindamin
BR9907866A (pt) Composição farmacêutica compreendendo uma combinação de metformina e fibrato, e seu uso para a preparação de medicinas destinadas a reduzir a hiperglicemia
DK0618900T3 (da) Substituerede tetrahydroisoquinoliner og deres anvendelse som terapeutiske midler
GEP20063799B (en) Tropane derivatives useful in therapy
UY27186A1 (es) Formulación farmacéutica
DE60143911D1 (de) Antitumorzusammensetzungen welche ecteinascidin 743 enthalten
ES2080307T3 (es) Composiciones farmaceuticas.
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
ATE243196T1 (de) Piperidine und pyrrolidine
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
ES2119748T3 (es) Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.
CR6834A (es) Complejos y composiciones de medicamentos macromoleculares que contienen lo mismo
NO20013012D0 (no) Transparent innretning for transdermal nikotinavlevering
KR890004690A (ko) 당뇨병의 치료를 위한 베자피브레이드의 용도
BR0108261A (pt) Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono
AR008025A1 (es) Combinación farmacéutica de una tiazolidindiona y un secretagogo de insulina
AR013352A1 (es) Uso de un sensibilizador a insulina y un agente antihiperglucemico para la preparacion de un medicamento para el tratamiento de la diabetes mellitus ycondiciones asociadas a la misma y una composicion farmaceutica.
AR007058A1 (es) Uso de interferon en medicamentos y composiciones para contacto oromucosal
ES2108642B1 (es) Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus.
DE59510583D1 (de) Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid